Biogenesis Bago awarded a contract with the United States Department of Agriculture to supply FMD vaccine bank to protect American livestock

The Animal and Plant Health Inspection Service (APHIS) of the United States Department of Agriculture (USDA) has chosen Biogenesis Bago as one of the official vaccines suppliers for its National Bank of Animal Vaccines and Veterinary Countermeasures (NAVVCB), a new initiative to reinforce livestock safeguard. The contract signed by Biogenesis Bago, a biotechnology company with presence in 25 countries in the Americas, Asia and Europe and worldwide leader in the fight versus Foot and Mouth Disease is for 17 years long. Additionally, the company also supplies since 2008 the North American Foot and Mouth Disease Vaccine Bank for USA, Canada and Mexico.

The Animal and Plant Health Inspection Service (APHIS) will invest $ 27.1 million in the vaccine to protect animals from local producers and stop the spread of the disease, in the event of an outbreak or emergency. The recently created National Bank of Animal Vaccines and Veterinary Countermeasures is an initiative included in the US Farm Bill 2018 to support the prevention and management of animal diseases and protect livestock Production. As reported by the entity, through this new bank the authorities seek to increase the country's level of protection against the disease and ensure that a much greater number of doses are available than it currently are through the Bank of Vaccines against Foot-and-Mouth Disease in North America (Mexico, United States and Canada).

North America and the United States in this particular case, is a zone free of this disease that affects livestock, so the defense of its sanitary status is crucial and demands the highest international quality and biosafety standards of concentrated antigens of FMD virus. The constant evolution of animal diseases throughout countries boarders demands constant prevention investments to preserve sanitary status in order to reach international markets.

Biogenesis Bago consolidates its position as a leader in animal health in various regions of the world. Its solid experience and its expansion to new markets are the result of the world class standard products, its highly qualified personnel and the constant investment in research and development that allows the company to access the most demanding markets in the world, diversifying its business and growing in a healthy way. 

"This contract enhance Biogenesis Bago´s commitment with animal health evolution worldwide", said Dr. Esteban Turic, corporate CEO. The new achievement was possible because of the commitment of the entire team of professionals and technicians at Biogenesis Bago. Consistent quality standards for its production processes to provide animal health solutions in the most diverse territories are the key for the company to provide high-value technologies from Argentina to the world.

Rodolfo Bellinzoni, COO and Innovation Director for Biogenesis Bago, also a world expert in this disease  highlighted: "We have many years of experience, developing technological solutions with high qualified human capital that allowed us to consolidate as a world referent in the fight against foot and mouth disease. It is validated with other important achievements as our endorsement as a key player in emergency campaigns during outbreaks in Argentina, Uruguay, Taiwan, South Korea and Vietnam. Also we are the only foreign company in China to produce FMD vaccine in the world largest market", Bellinzoni added. 

About Biogenesis Bago

Biogénesis Bagó is an international biotechnology company with more than 80 years of experience, specialized in the development, production and commercialization of products for animal health and productivity. Through scientific innovation of world reference, together with the certified quality of its processes and products (GMP, ISO 9001 and 14001), contributes to the search of veterinary solutions for a greater productive efficiency.

The company occupies the 3rd position in sales in the market of large animals of Latin America and became the largest regional company of the sector. In its productive model  plants Biogenesis Bago has more than 800 specialized collaborators and it is permanently developing new technologies for animal health.

The link with scientific, technological and sanitary authorities in the world contributes to develop the appropriate advances to fulfill the needs of each context, and today 3 out of every 10 cattle in South America receive the Biogenesis Bago FMD vaccine, which with its vaccination programs helped Eradicate foot-and-mouth disease in most countries of the continent. In addition, today it is the only company with products approved to be used in case of appearance of FMD disease in the United States and Canada.

Its commitment to the agro-food chain allows it to work with the conviction that it can contribute the best solutions for animal health, share its knowledge and experience, and accompany daily producers and veterinarians in the challenge of producing more and better food for the world.

For further information please contact Ángeles de San Segundo 011-15-3363-9149 maria.desansegundo@biogenesisbago.com